Osteopontin as a Biomarker in Interstitial Lung Diseases

Area of Science:

• Biochemistry
• Immunology
• Pulmonology

Background:

• Osteopontin (OPN) is a glycoprotein implicated in immune responses and tissue remodeling.
• OPN is recognized as a biomarker for disease activity in autoimmune inflammatory conditions.
• Its role in interstitial lung diseases (ILDs) requires further investigation for diagnostic and prognostic potential.

Purpose of the Study:

• To evaluate the diagnostic and prognostic value of osteopontin (OPN) in patients with interstitial lung diseases (ILDs).
• To compare serum OPN levels between ILD patients and healthy controls.
• To assess the correlation of OPN levels with disease severity and patient outcomes.

Main Methods:

• Serum OPN levels were measured using ELISA in 344 ILD patients and 140 healthy controls.
• OPN RNA expression and six genetic polymorphisms were analyzed.
• Patients were prospectively followed for survival and clinical outcomes.

Main Results:

• Serum OPN levels were significantly higher in ILD patients compared to healthy controls (p < 0.01).
• Elevated OPN levels correlated inversely with forced vital capacity and were higher in patients who died or underwent lung transplantation (p = 0.05).
• Survival analysis indicated worse outcomes for ILD patients with OPN levels above 1.03 ng/mL.

Conclusions:

• Elevated serum osteopontin (OPN) levels are associated with interstitial lung diseases (ILDs).
• Serum OPN may serve as a valuable indicator for identifying ILD patients at higher risk of adverse outcomes.
• No significant differences in OPN genetic polymorphisms or RNA expression were observed across ILD subtypes.